About the Product

Zorbtive® [somatropin (rDNA origin) for injection] is indicated for the treatment of Short Bowel Syndrome (SBS) in patients receiving specialized nutritional support. Zorbtive® therapy should be used in conjunction with optimal management of SBS. 

IMPORTANT SAFETY INFORMATION

Some common side effects of Zorbtive® treatment include muscle and joint pain, and fluid retention (swelling). Zorbtive® may also cause serious side effects such as inflammation of the pancreas (pancreatitis), diabetes or other blood sugar problems, pain, numbness or tingling in the wrist and hand, or increased blood pressure in the brain. Growth hormone therapy should not be initiated in patients with acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma or acute respiratory failure. Zorbtive® is contraindicated in the presence of active neoplasia (either newly diagnosed or recurrent). Any anti-tumor therapy should be completed prior to starting therapy with Zorbtive®. Zorbtive® is reconstituted with Bacteriostatic Water for Injection, USP (0.9% Benzyl Alcohol) and should not be administered to patients with a known sensitivity to Benzyl Alcohol.

Review full Prescribing Information and visit www.zorbtive.com for more information.  You can also call AXIS toll free at 1-877-714-AXIS (2947).

This information is not intended to replace discussions with your healthcare professional.  Please read the Zorbtive® Patient Information Leaflet and Zorbtive® Full Prescribing Information and talk to your doctor. 

Zorbtive® is for use by adults only.

Zorbtive® is available by prescription only.

NutreStore® and Zorbtive® are marketed in the U.S. by Emmaus Medical, Inc.

Disclaimer. This site contains medical information that is intended for residents of the United States only and is not meant to be a substitute for the advice provided by a medical professional. Always consult a healthcare provider if you have health concerns.